A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-a (ERa). Previous investigation suggests that methylation of CpGs within the ERa promoter mediates repression of gene expression in some ERa-negative breast cancers. To determine if methylation of CpGs within the ERa promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ERa gene in 40 ERa-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylationsensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P50.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ERa gene in BRCA1-linked breast cancers.
Introduction
BRCA1 is a breast cancer susceptibility gene, germline mutations of which are linked to a significant proportion of hereditary breast cancers (Miki et al., 1994) . Although the precise mechanisms by which mutations of BRCA1 predispose the carrier to breast cancer are at present unknown, loss of the wild type allele appears to be a required event, thereby fulfilling the paradigm of a tumor suppressor gene (Neuhausen and Marshall, 1994; Cornelis et al., 1995) . The functions of the BRCA1 protein that underlie its anti-oncogenic function are currently the subject of widespread investigation. BRCA1 is indeed a multifunctional protein, implicated in three broadly defined cellular functions: transcriptional regulation, DNA repair, and cell cycle check point control (for a detailed review of the literature see Wang et al., 2000; Zheng et al., 2000; Welcsh et al., 2000) . Nevertheless, studies thus far have yet to draw a conclusive association between any one of these functional roles and breast carcinogenesis.
Investigators have sought to identify characteristic phenotypic features of BRCA1-linked breast cancers. cDNA array assessments of mRNA expression profiles have suggested that these tumors exhibit distinctive patterns of gene expression (Hedenfalk et al., 2001; Berns et al., 2001 ; Van't Veer et al., 2002) . Immunohistochemical analyses have revealed that between twothirds and 90% of BRCA1-linked breast cancers are ERa-negative, making this one of the most distinguishing biological features of breast cancers that arise in carriers of a BRCA1 mutation (Loman et al., 1998; Jo´hannsson et al., 1997; Karp et al., 1997) . Recent data from Vaziri et al. (2001) suggest that the ERa-negative phenotype is primarily a distinctive feature of BRCA1-linked breast cancers arising in women before menopause. Since one of the earliest molecular steps towards breast carcinogenesis is likely to be loss of the wild type copy of BRCA1, the predominance of ERanegativity in the subsequent cancers suggests that either the ERa-negative phenotype has a selective advantage, or expression of ERa is compromised when BRCA1 is absent. Considering the importance of estrogen-based signaling in the genesis and progression of breast cancer, this characteristic of BRCA1-deficient breast cancers has important consequences for treatment and prevention. As there is not a documented association between BRCA1-linked breast cancers and ERb, this paper will only address the association with ERa.
ERa-negative breast cancers lack ERa mRNA, however the ERa gene is generally not mutated (Barrett-Lee et al., 1987; Piva et al., 1990; Yaich et al., 1992) . Cytosine methylation within a dense cluster of CpG dinucleotides (i.e. CpG island) just downstream of the transcription initiation site of the P1 promoter of the ERa gene has been implicated as an epigenetic mechanism of transcriptional repression in ERa-negative cell lines and primary tumors. Ferguson et al. (1995) reported that inhibition of DNA methyltransferase in selected ERa-negative cell lines resulted in reexpression of the ERa gene. Lapidus et al. (1996) analysed DNA from ERa-negative primary breast cancers by Southern analysis with a methylation-sensitive restriction site, NotI, and detected methylation in 25% of the specimens. Later, this same group used MSP, a method by which bisulfite-treated DNA is amplified by primers specific for either methylated or unmethylated DNA, to document increased methylation at selected CpG sites in ERanegative breast tumors as compared with ERa-positive tumors (Lapidus et al., 1998) . Iwase et al. (1999) using PCR amplification across HpaII methylation-sensitive restriction sites as a measure of CpG methylation, more recently demonstrated methylation in *80% of ERa-negative breast cancers. Of note, Iwase et al. (1999) also identified CpG methylation at HpaII sites in proximity to an upstream promoter (P0), but methylation at P0 was less clearly associated with the ERa-negative phenotype.
To determine if methylation of CpG dinucleotides within the P1 promoter of ERa is associated with BRCA1-linked breast cancers, we evaluated methylation at CpGs in exon 1 of the ERa gene, from 7212 bps upstream to +240 bps downstream of the ATG start codon. Genomic DNA was prepared from formalin-fixed sections from 40 ERa-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG sites were evaluated for methylation by one of the following three methods: HpaII digestion, MSP, or sequence analysis of bisulfitetreated genomic DNA. We demonstrate here a significantly higher level of CpG methylation in BRCA1-linked ERa-negative breast cancers compared with ERa-negative breast cancers that are not attributable to a germline mutation in BRCA1.
Results
We began our investigation by analysis of cell line DNA using two independent established methods that previously have been employed to document methylation at specific CpG sites within the ERa promoter. The first method, PCR amplification of genomic DNA after restriction digest with the methylation-sensitive enzyme HpaII, does not require bisulfite treatment of the DNA. With this approach, Iwase et al. (1999) documented methylation at two CpG sites within exon 1 in *80% of ERa-negative primary breast cancers. The second method we employed was MSP analysis of bisulfite-treated DNA. Of the six primer pairs tested by Lapidus et al. (1998) we selected ER1 and ER5. We chose the ER1 primer pair because the CpG situated at the 3' end of the lower ER1 primer is within the ERF-1 binding site, reported to play a role in ERa expression in some breast cancer cell lines (DeConinck et al., 1995) . We chose the ER5 primer pair because MSP with these primers yielded the most significant difference in CpG methylation as a function of receptor expression in primary breast cancers (Lapidus et al., 1998) .
Four ERa-negative cell lines were studied: MCF10A and 184B5 are both immortalized nontumorigenic mammary epithelial cell lines, MDA-MB-231 is a breast cancer cell line for which a large body of data regarding CpG methylation already exists, and HCC1937 is a recently developed cell line derived from a breast cancer arising in a woman with a germline mutation in BRCA1 (Tomlinson et al., 1998) . The left panel of Figure 1 shows PCR products of genomic DNA from each cell line after digestion with HpaII. By this assay, both the MCF10A and MDA-MB-231 cell lines showed notable methylation as evidenced by the presence of a PCR product in the HpaII digest lane, whereas the 184B5 and HCC1937 cells showed lack of methylation.
Results from MSP analysis of bisulfite-treated cell line DNA are illustrated in the right-hand panel of Figure 1 . MCF10A cells showed the strongest overall methylation signal, especially within the ER1 region, while HCC1937 cells were totally unmethylated as indicated by lack of a PCR product with the methylated DNA-specific primers. Data from the HpaII digests most closely correlated with ER5 MSP data, as would be expected since one of the HpaII CpG sites is within the lower ER5 primer region while the other HpaII CpG is just 4 bps downstream of the lower ER5 primer. MSP analysis of DNA from three of the cell lines demonstrated the presence of both methylation and unmethylation at ER1 and/or ER5. This may reflect the fact that CpG methylation is often significantly less than 100%, as we have reported in an analysis of methylation at the TGF-b3 promoter (Archey et al., 1999) . Alternatively, this apparent heterogeneity within cell line DNA could have resulted from incomplete bisulfite-mediated conversion of unmethylated cytosines. To resolve this issue, and to provide data on the methylation status of significantly more than the handful of CpG sites queried by the above-utilized approaches, we performed sequence-based analysis of the bisulfite-treated DNA. The ER1 and ER5 regions were amplified from bisulfite-treated DNA with degenerate primers, such that both methylated and unmethylated template DNA would be co-amplified. The resulting PCR products were then directly sequenced, thereby providing data on 25 CpGs located within the amplified regions. Conversion of the non CpG cytosines was 495%, indicating that incomplete bisulfite treatment was not the reason for heterogeneity of methylation noted in the MSP analysis. Having established that comprehensive analysis of CpG methylation in this region of the ERa promoter, by three independent methods, could be performed with as little as 200 ng of cell line DNA, we turned our attention to analysis of DNA from a collection of ERa-negative primary tumor specimens, half of which were linked to BRCA1. Given that the HCC1937 cell line demonstrated minimal methylation throughout this region, we first analysed DNA isolated from patient specimens to test the hypothesis that BRCA1-linked tumors would show significantly less methylation than the non-linked specimens. For this purpose, we applied a method with perhaps the highest sensitivity for the presence of CpG methylation: PCR amplification following digestion of DNA with a restriction enzyme that will leave uncut templates with methylated CpGs at the restriction site. As previously discussed, using this methodology, Iwase et al. (1999) reported that *80% of ERa-negative breast cancers from women Figure 2 CpG methylation of the ERa promoter in four ERa-negative cell lines. Bisulfite-treated DNA from each cell line was amplified with degenerate primers for the ER1 and ER5 regions, and then sequenced as described in Materials and methods. CpG location is indicated (x axis) relative to the first nucleotide of P1. MCF10A cells, MDA-MB-231 cells, 184B5 cells, and HCC1937 cells are shown without a positive family history showed methylation at two CpG sites within a HpaII site in proximity to the ER5 downstream primer. Analysis of HpaII digested DNA from the patient specimens demonstrated significant methylation (94%) within the BRCA1-linked specimens (data not shown). Among the non BRCA1-linked group 81% showed methylation, consistent with the published data of Iwase et al. (1999) . While the difference between the BRCA1-linked and non-BRCA1-linked groups was not statistically significant (P40.2), these data negate the hypothesis that BRCA1-linked breast cancers are largely unmethylated at the ERa locus, as was the case with the HCC1937 cell line, and that in this context the HCC1937 cell line is not representative of primary BRCA1-linked breast cancers.
As a semi-quantitative measure of the relative abundance of methylated and unmethylated DNA at the ER1 primer binding sites, we amplified bisulfitetreated DNA with the methylated DNA-specific primer pair as well as with the degenerate primer pair in parallel amplification reactions and compared the relative intensity of the resulting PCR products on an agarose gel (data not shown). In separate reactions utilizing synthesized templates representing methylated and unmethylated ER1 sequence, we determined that PCR products of equal intensity with these primer pairs resulted when the methylated DNA template constituted *10% of the total, reflecting a lower efficiency of amplification with the degenerate primers (not shown). We observed that whereas only one out of 12 samples in the non BRCA1-linked group produced a PCR band of greater intensity with the methylated DNA-specific primers than with the degenerate primers, half of the BRCA1-linked group (four out of eight) yielded a PCR band of greater intensity with the methylated DNA-specific primers than with the degenerate primers. Although this represents a significant difference between the two groups (P=0.035 by Chi-Square analysis), the limited number of both specimens and CpG sites evaluated diminished the interpretive power of these data. We therefore decided to devote the limited amount of DNA from the tumor specimens available to the more comprehensive sequence-based analysis of bisulfite-treated DNA in order to test the hypothesis that CpG methylation at the ERa promoter is increased in ERa-negative BRCA1-linked breast cancers.
Bisulfite-treated DNA from the tumor specimens was amplified with degenerate primers for both the ER1 and ER5 regions, and then analysed by DNA sequencing to ascertain the per cent methylation at each of 25 CpG sites (see Materials and methods for a full description of this assay). Figure 3 illustrates the average methylation at each CpG for the non-BRCA1-linked and BRCA1-linked breast cancer groups. Methylation was higher at most CpG sites in the BRCA1-linked breast cancers as compared to the non-BRCA1-linked breast cancers in both the ER1 and ER5 regions (Figure 3a,b, respectively) . The overall average percent methylation was 25% among non-BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). Specifically within the ER1 regions, the overall average per cent methylation was 24 and 43% (P=0.0041) respectively, and within ER5, 27 and 39% (P=0.0094) respectively. There were no significant differences in the overall average per cent methylation between the ER1 and ER5 regions in the primary specimens. Of note, five of the 25 examined CpGs, located at positions 62, 68, 121, 129 (Figure 3a) , and 423 (Figure 3b) , exhibited a greater than twofold increase in average methylation in the BRCA1-linked group compared to the non-BRCA1-linked group (P50.03).
Of the 25 CpG sites investigated by sequencing, eight demonstrated significantly more methylation in the BRCA1-linked specimens compared with the non-BRCA1-linked specimens (P50.03 for each CpG), five of which demonstrated no overlap in the 95% a b Figure 3 CpG methylation of the ERa promoter in primary breast cancer samples. Bisulfite-treated DNA from each primary section was amplified with degenerate primers for the ER1 (a) and ER5 (b) regions, and then sequenced as described in Materials and methods. The average per cent methylation, +95% confidence interval, for non BRCA1-linked breast cancers and BRCA1-linked breast cancers is indicated for each CpG site. Significant differences between the two groups are illustrated as P50.05 (*), P50.03 (**) and P50.01 (***) confidence intervals (P50.01 for each CpG). Data from the individual specimens for the panel of eight discriminative CpG sites are presented in Figure 4 . It is evident from examination of the individual data points that clear outliers do exist for both the non-BRCA1-linked and BRCA1-linked groups.
Discussion
Perhaps the most distinctive pathologic feature of breast cancers that arise in women who inherit a mutation in BRCA1 is a lack of expression of ERa. Mechanisms associated with the ERa-negative phenotype in breast cancer cell lines include absence of requisite transcription factors, presence of DNAbinding factors that repress transcription, and epigenetic changes such as DNA methylation and histone deacetylation (Ferguson et al., 1995; Tang et al., 1997; McPherson et al., 1997; Penolazzi et al., 2000; Yang et al., 2000) . Analysis of DNA from primary breast tumors has revealed methylation of CpGs within exon 1 of the ERa gene in a significant portion of ERanegative cancers, but rarely in ERa-positive tumors. The present study was done to determine whether the ERa-negative phenotype among BRCA1-linked breast cancers was similarly associated with CpG methylation. We observed that ERa-negative breast cancers arising in BRCA1 mutation carriers were even more extensively methylated than ERa-negative cancers from women without a BRCA1 mutation. A potential weakness in our analysis is that microdissection of the tumor cells away from normal cells, which would contribute DNA that is unmethylated at this locus, was not performed.
Approximately 10% of BRCA1-linked specimens showed low levels of methylation (Figure 4) . Thus, even within this relatively homogeneous collection of tumors, there was evident heterogeneity in methylation. Clearly, not all ERa-negative breast cancers that develop in BRCA1 mutation carriers arise via the same sequence of cancer-promoting cellular changes. Noting that the HCC1937 cell line was also minimally methylated in this region, it seems likely that this line originated from a breast cancer that is representative of the *10% of BRCA1-linked ERa-negative tumors lacking hypermethylation in this region. Although not studied here, we would expect CpG methylation to be absent in the 10 -30% of BRCA1-linked breast cancers that do express ERa.
From our sequence-based analysis of multiple CpG sites, we observed that the degree of methylation differed somewhat from one CpG to another, which might explain why different methods that are based on only a few CpG sites could generate different estimates of the frequency of methylation. Furthermore, although an overall higher level of methylation in the BRCA1-linked specimens was found throughout the analysed portions of the ERa gene, a subset of the CpG sites provided the greatest distinction between BRCA1-linked and non-BRCA1-linked tumors. We hypothesize that methylation of these most discriminating CpGs is integral to the mechanism by which loss of BRCA1 function results in the lack of ERa expression.
A correlation between loss of BRCA1 and the ERanegative phenotype may extend to a substantial portion of sporadic breast cancers as well. In recent years various investigators have reported that approximately 20 -35% of sporadic invasive ductal carcinomas expressed very low or undetectable levels of BRCA1 protein (Wilson et al., 1999; Yoshikawa et al., 1999) . Furthermore, sporadic breast cancers that lack BRCA1 expression, in some instances due to CpG methylation within the BRCA1 promoter, may be more likely to be ERa-negative (Catteau et al., 1999) . From the data in Figure 4 it is evident that approximately 25 -40% of the ERa-negative non BRCA1-linked specimens showed a high degree of CpG methylation, to the level that was characteristic of the BRCA1-linked group. We therefore hypothesize that decreased expression of BRCA1 in a subset of sporadic breast cancers results in loss of ERa expression via CpG methylation. Correlation of BRCA1 expression with ERa methylation status in a collection of sporadic cancers would serve to test this hypothesis.
There are no available data concerning a direct role of BRCA1 regarding the expression or function of any of the known DNA methyltransferases, or demethylase enzymes. BRCA1 has been reported to physically associate with components of the histone deacetylase complex, although the functional consequences of these interactions are unclear (Yarden and Brody, 1999 ). An evolving notion in the literature is that a dynamic interplay between histone acetylation and CpG methylation, whereby each influences the other, acts as a mechanism to magnify and perpetuate epigenetic Figure 4 Distribution of methylation at significant CpG sites (P50.03) as indicated by individual primary breast cancer sections. Per cent methylation for each non BRCA1-linked breast cancer specimen and BRCA1-linked breast cancer specimen is shown at the eight most discriminative CpG sites. Methylation within the BRCA1-linked group is significantly higher than in the non BRCA1-linked group at each CpG site (P values from left to right are 0.0076, 0.0006, 0.0057, 0.022, 0.0279, 0.0218, 0.0082 and 0.002) control of gene expression (Dobosy and Selker, 2001; Cervoni and Szyf, 2001) . Considering the large number of genes whose expression level has been reported to differ as a function of BRCA1 expression, it is intriguing to suggest that BRCA1 influences an important epigenetic network that affects the expression of multiple genes.
In summary, we have observed that CpG methylation in ERa-negative breast cancers is significantly more extensive among BRCA1-linked tumors. If expression of ERa within mammary epithelial cells lacking BRCA1 can be induced by compounds that inhibit DNA methylation or histone deacetylation, the clinical development of such agents may be of particular use to reverse some of the epigenetic consequences of the loss of BRCA1 in breast cancer.
Materials and methods

Cell culture
Cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). MCF10A and MDA-MB-231 cells were cultured in DMEM : Ham's F-12 medium, supplemented with 100 IU/ml of penicillin, 125 mg/ml of streptomycin, 2 mM L-glutamine and 10% fetal bovine serum. MCF10A culture medium was additionally supplemented with 20 ng/ml of epidermal growth factor, 0.5 mg/ml of hydrocortisone and 8 mg/ml of insulin. 184B5 cells were cultured in MEBM medium (Clonetics, Walkersville, MD, USA), supplemented with penicillin, streptomycin and Lglutamine as above, in addition to 5 ng/ml of epidermal growth factor, 0.5 mg/ml of hydrocortisone, 5 mg/ml of insulin, 5 mg/ml of transferrin and 10 75 M isoproterenol. HCC1937 cells were cultured in RPMI 1640 medium with Lglutamine, supplemented with 125 mg/ml streptomycin and 10% fetal bovine serum.
Patient specimens
Paraffin-embedded, formalin-fixed specimens that met the following criteria were obtained from collaborating institutions. At the originating institution, tumors were determined to be ERa-negative by immunohistochemistry and were histologically classified as either infiltrating ductal or medullary. The BRCA1-linked specimens came from women with a pathogenic germline BRCA1 mutation. The non-BRCA1-linked specimens came from women who either had no first degree relative with breast or ovarian cancer, and therefore had a negligible a priori risk of being a BRCA1 mutation carrier, or had undergone genetic testing and did not carry a detectable BRCA1 mutation. The average age at diagnosis for the BRCA1-linked group (43+12 years) did not differ significantly from the average age at diagnosis for the non BRCA1-linked group (50+11 yrs).
DNA isolation
Cell line genomic DNA was isolated from adherent cells using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA). For preparation of DNA from breast cancer specimens, 10 -20 micron sections were first deparaffinized with Stephens Clearing Solvent (Stephens Scientific, Riverdale, NJ, USA), washed twice in 100% ethanol and dried at 378C in a sandbox. Digestion of tissue and isolation of genomic DNA was performed using the Qiagen DNA Mini Kit (Qiagen, Valencia, CA, USA). Tissue digestion was performed overnight at 568C with 12 -36 mAU proteinase K, and genomic DNA was eluted in 300 ml H 2 O. One-half of each sample was apportioned to analysis of non bisulfite-treated DNA, i.e. HpaII digest, while the other half was apportioned to analysis of bisulfite-treated DNA, i.e. MSP and sequencing of genomic DNA.
HpaII digests
A modified procedure from Iwase et al. (1999) was used for HpaII digests. In brief, one hundred nanograms of cell line DNA, or alternatively one-sixth of the total DNA isolated from a given primary tumor sample, was subjected to restriction digest with 50 U of HpaII (NE Biolabs, Beverly, MA, USA) or no enzyme in 0.56Universal Buffer (Stratagene, La Jolla, CA, USA) in a final volume of 30 ml. Digestion took place for 20 h at 378C. One third of the digestion reaction was used for PCR amplification of a 230 bp region using the following primers: upper 5'-AGCAGCAAGCCCGCCGTGTACAAC-3', lower 5'-GGG-CTGCAGGAAAGGCGACAGC-3'. Each PCR reaction contained 50 mM KCl, 1.5 mM MgCl 2, 0.2 mM each dNTP, 0.5 mM each primer, and 2.5 U Taq Platinum (Gibco, Gaithersburg, MD, USA) in a total volume of 60 ml with 20 mM Tris-HCl (pH 8.8). PCR reaction conditions were as follows: initial soak of one cycle at 958C for 5 min, followed by 38 cycles at 948C for 30 s, 678C for 30 s and 728C for 30 s, followed by extension for one cycle at 728C for 10 min. One half of the total PCR volume was resolved on a 1.2% TBE-agarose gel, stained with ethidium bromide and visualized by UV transillumination.
Bisulfite modification of DNA
Genomic DNA apportioned to MSP and sequencing analysis was supplemented with 1 mg of salmon sperm DNA as a carrier, and denatured in a volume of 50 ml in the presence of 0.2 M NaOH at 378C for 10 min. As outlined by Herman et al. (1996) , denatured DNA was treated with sodium bisulfite, desalted using the Wizard DNA Clean-Up System (Promega, Madison, WI, USA) and desulphonated with 0.3 M NaOH at room temperature for 5 min. DNA was then precipitated in EtOH and resuspended in TE buffer for storage at 7808C.
MSP and amplification of bisulfite-treated DNA with degenerate primers
Approximately one-tenth of the total DNA isolated from a given primary tumor sample, or 30 ng of cell line DNA, was used as template for PCR after bisulfite treatment. A modified procedure of Lapidus et al. (1998) was used for PCR amplification using the primer sets designated as ER1 and ER5. In brief, each PCR reaction contained 16PCR buffer prepared fresh (16.6 mM ammonium sulfate, 67 mM Tris-HCl (pH 8.8), 6.7 mM M g Cl 2 and 10 mM b-mercaptoethanol), 1.25 mM each dNTP, 150 ng each primer, and DNA template in a final volume of 25 ml. Reactions with ER1 primers contained 0.72 U Taq Platinum and reactions with ER5 primers contained 0.63 U Taq Platinum. ER1 degenerate primer sequences were as follows: upper 5'-TTTTGGGATTGTATTTGTTTTYGTYG-3', and lower 5'-AACAAAATACAAACCRTATCCCCR-3'. These primers correspond to nucleotides 21 -45, and 193 -217, relative to the first nucleotide of transcription from P1. ER5 degenerate primer sequences were as follows: upper 5'-GTGTATTTG-GATAGTAGTAAGTTYGTY-3', and lower 5'-CRTAAAA-AAAACCRATCTAACCR-3'. These primers correspond to nucleotides 355 -381, and 450 -472, relative to P1. Degenerate primers were characterized by 'Y' or 'R' sites shown in bold, which designate a 50/50 mixture of cytosines and thymines (Y), or guanines and adenines (R). Each PCR reaction underwent initial denaturation at 958C for 5 min, followed by either 42 cycles (ER1) or 40 cycles (ER5) of the following profile: 30 s at 948C, 30 s at 588C (ER1) or 30 s at 558C (ER5), and 30 s at 728C. Each reaction completed its PCR cycle profile with a 10 min extension at 728C. For each primary breast cancer sample, three PCR reactions were performed: ER1 with methylated-DNA specific primers, ER1 with degenerate primers, and ER5 with degenerate primers. Seventeen microliters of each 25 ml reaction was resolved on a 2% TBE-agarose gel, stained with ethidium bromide and visualized by UV transillumination.
Sequencing of PCR reaction products
PCR products from bisulfite-treated DNA using the degenerate primers were reamplified using the same degenerate primers and PCR conditions, and 5 ml of the previous reaction as a template. Reamplified PCR products were purified using the Qiagen PCR Clean Up Kit (Qiagen, Valencia, CA, USA) and sequenced using the ABI Prism Big Dye Terminator Cycle Sequencing System (Perkin Elmer Corp., Foster City, CA, USA). ER1 and ER5 degenerate primers were used for sequencing via primer extension with the following conditions: 10 s at 968C, 5 s at 508C and 4 min at 608C for 25 cycles. Sequencing reaction solutions were purified using Centriflex Gel Filtration Cartridges (Advanced Genetic Technologies, Gaithersburg, MD, USA). Per cent methylation levels were calculated from the fluorescence intensities at the CpG sites of interest. The levels of cytosine (the presence of which indicates methylation as sodium bisulfite did not convert it) and thymine (the presence of which indicates unmethylation as sodium bisulfite did convert it) fluorescence peak heights were used as a reflection of the fraction of DNA in the sample that was methylated at that position. Since nucleotide fluorescence peak heights can vary in intensity depending on their location within a given sequencing region, peak height ratios were normalized using a standard curve based upon sequencing reactions with defined mixtures of plasmid DNA containing ER1 and ER5 DNA sequence representative of methylated and unmethylated DNA after bisulfite treatment. Oligonucleotides were designed and synthesized to reflect bisulfite-converted methylated and unmethylated DNA, amplified with the ER1 and ER5 primers, and subcloned into a pCR 2.1 vector (Invitrogen, Carlsbad, CA, USA). Column-purified plasmid preparations incorporating sequences representative of either fully methylated or unmethylated DNA were combined (mixtures containing 10, 25, 33 and 50% of DNA sequence reflective of CpG methylation) and sequenced, and a standard curve was determined for each CpG position using a linear regression formula. The known fraction of methylated DNA was plotted against the cytosine to thymine peak height ratios taken from the sequencing electropherograms to establish the standard curve, against which per cent methylation at each CpG site in each tumor specimen was determined.
Statistical analyses
Significance of the per cent methylation among primary breast cancer samples in Figures 3 and 4 was calculated using a two-tailed, nonparametric Mann -Whitney test suitable to data sets with skewed distributions.
